María Isolina Santiago-Pérez

María Isolina Santiago-Pérez

Auto-generated profile, based on publicly available information

María Isolina Santiago-Pérez

Directorate‐General of Public Health Galician Regional Health Authority, Epidemiology Department Santiago de Compostela Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in European Journal of Public Health
Verified
Journal Article
Open access
CTCarla Guerra Tort
Carla Guerra Tort
ELEsther López-Vizcaíno
Esther López-Vizcaíno
MSMaría Isolina Santiago-Pérez
María Isolina Santiago-Pérez
JRJulia Rey-Brandariz
Julia Rey-Brandariz
CCCristina Candal-Pedreira
Cristina Candal-Pedreira
MPMonica Pérez-Ríos
Monica Pérez-Ríos
The aim of this study was to estimate the series of tobacco smoking prevalence year-by-year in Spain, by sex and age group, for the period 1991–2020. Based on smoking prevalence obtained from national surveys and smoking-related auxiliary information from public statistics, we fitted a multinomial logistic mixed model with random area and time effects. Joinpoint regression was used to identify changes in the prevalence series across the period. To analyse the precision of the model-based estimates, we calculated the coefficients of variation. Between 1991 and 2020, the prevalence of smoking in Spain decreased in both sexes. In the 15–24 age group, the prevalence of smokers showed no differences by sex until 2007, after which prevalence in men exceeded that of women. However, in women aged 55 and over prevalence of smoking has been rising since 1991. After applying the model, the precision of smoking prevalence estimates improved. The reconstruction of a detailed series of tobacco smoking prevalence provides insight into the evolution of the tobacco epidemic in Spain. A detailed analysis by sex and age shows different trends in the prevalence of smoking among women that should be considered when control measures are formulated.

1 January 2021 in Revista Brasileira de Epidemiologia
Verified
Journal Article
Open access
PDF file
AGAlexandra Giraldo-Osorio
Alexandra Giraldo-Osorio
RMRafael da Silveira Moreira
Rafael da Silveira Moreira
PNPaulino Alburquerque Neto
Paulino Alburquerque Neto
MSMaría Isolina Santiago-Pérez
María Isolina Santiago-Pérez
JRJulia Rey
Julia Rey
MPMonica Pérez-Ríos
Monica Pérez-Ríos
RESUMEN: Objetivo: Actualizar la estimación de la mortalidad atribuida al consumo de tabaco en Brasil en población de 35 y más años. Métodos: Se aplicó un método dependiente de prevalencia, basado en la fracción atribuida poblacional. Este método estima la mortalidad atribuida a partir de la mortalidad observada en Brasil (fuente: Sistema de Información de Mortalidad del Sistema Único de Salud de Brasil-2016); de las prevalencias de fumadores, exfumadores y nunca fumadores (Encuesta Nacional de Salud de Brasil-2013) y del exceso de riesgo de morir (riesgo relativo) que tienen los fumadores y exfumadores en comparación con los nunca fumadores (5 estudios de cohortes norteamericanos). Se presentan estimaciones de mortalidad atribuida globales, por sexo, grupo de edad (35-54; 55-64; 65-74 y 75 años en adelante) y 3 grupos de enfermedades: tumores malignos, enfermedades cardiometabólicas y respiratorias. Resultados: En 2016, el consumo de tabaco causó con 163.831 muertes en Brasil, el 67% (109.369) fue en hombres y cuatro de cada diez (62.791) sucedieron antes de los 65 años. El 42% de la mortalidad atribuida se asocia a enfermedades cardiometabólicas, seguidas de respiratorias (34%) y tumorales (24%), sin diferencias por sexo. Conclusión: El 14% de las muertes que sucedieron en Brasil durante 2016 en población de 35 y más años se atribuye al consumo de tabaco. Realizar de forma periódica estimaciones de MA es necesario para valorar y fortalecer las leyes de control de tabaquismo implantadas.

1 September 2023 in Tobacco Induced Diseases
Verified
Journal Article
Open access
CTCarla Guerra Tort
Carla Guerra Tort
ELEsther López-Vizcaíno
Esther López-Vizcaíno
MSMaría I. Santiago-Pérez
María I. Santiago-Pérez
JRJulia Rey-Brandariz
Julia Rey-Brandariz
CCCristina Candal-Pedreira
Cristina Candal-Pedreira
MPMonica Pérez-Ríos
Monica Pérez-Ríos
Introduction: Small-area estimation methods are an alternative to direct surveybased estimates in cases where a survey’s sample size does not suffice to ensure representativeness. Nevertheless, the information yielded by small-area estimation methods must be validated. The objective of this...

26 January 2026 in Annals of Neurology
Verified
Journal Article
Open access
MMMarta Mascareñas‐García
Marta Mascareñas‐García
ARAlejandro Rivero‐De‐Aguilar
Alejandro Rivero‐De‐Aguilar
CCCristina Candal‐Pedreira
Cristina Candal‐Pedreira
GGGuadalupe García
Guadalupe García
CTCarla Guerra Tort
Carla Guerra Tort
Maria Leonor Varela LemaMaria Leonor Varela Lema
Maria Leonor Varela Lema
Objective: Spin refers to reporting strategies that highlight the benefits of an experimental treatment or divert attention from nonsignificant primary outcomes. We aimed to assess spin in randomized controlled trials (RCTs) on pharmaceutical efficacy in multiple sclerosis (MS) and explore associated factors. Methods: A systematic literature search was conducted in MedLine (PubMed), EMBASE, and Cochrane using database‐specific thesauri (“Multiple Sclerosis” and “Drug Therapy”) to identify relevant studies. We included multiple sclerosis phase 3 and 4 randomized controlled trials with parallel, superiority designs that were published between 2013 and 2024 reporting nonsignificant primary outcomes. Spin was assessed in title, abstract conclusion, results, discussion, and conclusions. A descriptive analysis was followed by exploratory bivariate logistic regression. Independent variables included trial phase, sample size, drug type, comparison, follow‐up time, registration, Consolidated Standards of Reporting Trials (CONSORT) mention, risk of bias (RoB2), journal quartile, first author affiliation, and conflict of interest. Results: Forty articles met inclusion criteria. Spin appeared in at least one section in 25 articles (62.5%) and in 3 or more in 19 articles (47.5%). The most frequent locations were abstract conclusions, discussion, and conclusions. Spin was significantly associated with smaller sample size (odds ratio [OR] = 7.00, 95% confidence interval [CI] = 1.29–37.91, p = 0.024), non‐Q1 journals (OR = 4.38, 95% CI = 1.03–18.63, p = 0.046), and first author affiliation outside Europe or the United States (OR = 5.09, 95% CI = 1.15–22.62, p = 0.032). Interpretation: Spin is common in MS randomized controlled trials with nonsignificant primary outcomes and may mislead clinical decisions. ANN NEUROL 2026;99:316–327

18 January 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
Alberto Ruano-RavinaAlberto Ruano-Ravina
Alberto Ruano-Ravina
ELEsther López-Vizcaíno
Esther López-Vizcaíno
CCCristina Candal-Pedreira
Cristina Candal-Pedreira
MSMaría Isolina Santiago-Pérez
María Isolina Santiago-Pérez
MPMonica Pérez-Ríos
Monica Pérez-Ríos
Background: Europe has had a large variability in COVID-19 incidence between and within countries, particularly after June 2020. We aim to assess the variability between European countries and regions located in a given country.Methods: We used ECDC information including countries having 7 regions or more. The metric used to assess the regional variability within a country was the intercuartilic range in a weekly basis for 32 weeks between June 29th 2020 and February 1st 2021. We also calculated each country's overall variability across the 32 weeks using the distances from the regional curves of the 14-day incidence rates to the corresponding national curve, using the L2 metric for functional data. We afterwards standardised this metric to a scale from 0 to 100 points. We repeated the calculations excluding island regions.Results: The variability between and within countries was large. Slovenia, Spain and Portugal have the greatest variability. Spain and Slovenia held also the top three places for the greatest number of weeks (Spain for 19 weeks and Slovenia for 10) with the highest variability. For variability among the incidence curves across the 32-week period, Slovenia, Portugal and Spain ranked first in functional variability, when all the regions were analysed but also when the island regions were excluded.Conclusions: These differences might be due to how countries tackled the epidemiological situation. The persistent variability in COVID-19 incidence between regions of a given country suggests that governmental action may have an important role in applying epidemiological control measures.

9 October 2025 in Annals of Epidemiology
Verified
Journal Article
Open access
MSMaría Isolina Santiago-Pérez
María Isolina Santiago-Pérez
CTCarla Guerra Tort
Carla Guerra Tort
ELEsther López-Vizcaíno
Esther López-Vizcaíno
LMLucía Martín-Gisbert
Lucía Martín-Gisbert
ATAna Teijeiro
Ana Teijeiro
MPMonica Pérez-Ríos
Monica Pérez-Ríos
The estimation of smoking-attributable mortality (SAM) is subject to the acceptance of different assumptions that may influence the estimates. We aimed to assess lung cancer attributable mortality by using both a prevalence-independent method (PIM) and a prevalence-dependent method (PDM) with different lags between exposure (smoking prevalence) and result (lung cancer mortality). We estimated the population attributable fractions (PAF) and the lung cancer SAM by sex and age group (35-64, 65-84 years), year-by-year from 2011 to 2020, in four scenarios in Spain. In three of these scenarios, a PDM was applied using different lags: no lag, a 15-year lag and a 20-year lag. In the fourth scenario, a PIM was applied. In the period 2011-2020 in Spain, the SAM was higher when the 20-year lag PDM was considered (173,526 deaths) and lower when no lag PDM or a PIM was applied (161,249 and 157,390 deaths, respectively). In men, the PAFs were similar between the no lag PDM and the PIM (86.7% and 87.3%, respectively). However, when a PDM 15-year or 20-year lag was considered, the PAF increased to 91.0% and 92.3%. In women, the lowest PAF was obtained with the PIM (57.3%), and the highest with the PDM 20-year lag (79.4%). SAM estimates differ depending on the methods and lags used. Applying a 15-year or 20-year lag PDM yields higher SAM estimates than when no lag PDM or an PIM is used. Therefore, when feasible, smoking prevalence data that incorporate a lag of 15 or 20 years between exposure and result should be used for accurate estimates.